90729-41-2
Chemical Structure
Oxodipine
- CAS No.: 90729-41-2
- Formula:C19H21NO6
- Molecular Weight:359.37
IUPAC Name: 3-ethyl 5-methyl 4-(benzo[d][1,3]dioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
InChIKey: MSOAVHHAZCMHDI-UHFFFAOYSA-N
SMILES: CCOC(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC3=C2OCO3)=O
Biological Activity: Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oxodipine | Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nyska A, et al. Gingival hyperplasia in rats induced by oxodipine‐a calcium channel blocker[J]. Journal of Periodontal Research, 1990, 25(2): 65-68. [Content Brief]
- [2]. Tamargo J, et al. Effects of oxodipine on 45Ca movements and contractile responses in vascular smooth muscle[J]. British journal of pharmacology, 1989, 97(2): 339. [Content Brief]
- [3]. Galán L, et al. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes[J]. European journal of pharmacology, 1998, 357(1): 93-105. [Content Brief]
- [4]. Egros F, et al. An original intragastric delivery system for oral administration of solid formulations to fully conscious rats: its application to oxodipine studies[J]. European Journal of Drug Metabolism and Pharmacokinetics, 1991: 71-76. [Content Brief]
- [5]. Montastruc P, et al. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs[J]. Archives internationales de pharmacodynamie et de thérapie, 1993, 321: 57-62. [Content Brief]
- [6]. Tejerina T, et al. Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels[J]. European journal of pharmacology, 1992, 219(2): 279-284. [Content Brief]
